37 results about "Severe asthma" patented technology

The invention provides methods for automated classification of a medical diagnostic image of a lung according to its deduced probability of relating to a lung of a patient who is suffering from a diffuse parenchymal lung disease such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, or severe asthma, or to a class of patients characterised by the severity of such a condition, or to a class of patients characterised by a prognostic likelihood of developing such a condition or severity of condition.

The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

The invention discloses dezocine freeze-dried powder injection. The dezocine freeze-dried powder injection consists of the following components by dosage: 0.5-50mg of dezocine/per injection, 1-25% of a freeze-dried excipient and 0.5-50mg of an antioxidant/per injection, wherein the pH value of the freeze-dried solution is regulated to 3.0-6.0 by use of a pH regulator. Compared with the commercially available preparation, the dezocine freeze-dried powder injection has the advantage that the auxiliary material components are not added with sodium pyrosulfite which is taken as the antioxidant, and the sulfate possibly causes fateful anaphylactic reaction and severe asthma for a susceptible person, so that certain potential safety hazards caused by the sulfate are avoided. The commercially available preparation is added with 30% of propylene glycol as an anti-freezing agent, and made into freeze-dried powder injection in which a special solvent is not needed for separation under a low temperature condition. In a preparation process of the dezocine injection, high-temperature sterilization is needed, and associated substances in the sterilization process are suddenly increased. Compared with the injection, the dezocine freeze-dried powder injection contains less associated substances without being sterilized at the high temperature; and meanwhile, the injection solids are easier to store than the liquid, so that the increase of the associated substances is less, and thus, additional risks are reduced for clinical application.

A resuscitation system for the administration of cardiopulmonary resuscitation of asthma patients, and for teaching the cardiopulmonary resuscitation of asthma patients. The invention includes a deflatable bag and a gas flow channel connected with said bag, for connection with an indwelling endotracheal tube so that gas can flow from the bag into the patient and from said patient through said flow channel, an exhalation port in flow connection with said flow channel and an indicator mounted adjacent said system for detecting expiration flow and/or pressure within at least one of said flow channel and exhalation port to detect inadequacy in the expiratory component of ventilation during CPR and to train healthcare workers in the emergency ventilation of severe asthmatic patients in the field and emergency room.

The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.

The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.

The invention belongs to the technical field of severe asthma action mechanisms, and discloses a medicine for relieving severe asthma, application and an animal model construction method, the medicine is an HDAC10 inhibitor, and the action mechanism of HDAC10 for regulating and controlling Th17/IL-17A expression in severe asthma is clarified by using the construction method; the interaction mode of HDAC10 and STAT3 is defined; it is proved that HDAC10 deacetylated STAT3 regulates and controls the expression of Th17/IL-17A in severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. Compared with a control group, the intraperitoneal injection of the HDAC10 inhibitor can improve airway inflammation, airway hyperreactivity and airway mucus secretion of a severe asthma mouse model mainly comprising neutrophile granulocytes.

The invention discloses a biomarker for severe asthma and application thereof. The biomarker is ENSG00000241587. The expression level of lncRNA (long non-coding Ribonucleic Acid) in blood samples of normal people, common asthma patients and severe asthma patients is detected, finding that the ENSG00000241587 has remarkable difference in the severe asthma for the first time, which shows that the ENSG00000241587 can be used as a detection target to be applied to auxiliary diagnosis of the severe asthma.

The present invention relates to a method of treating allergic asthma in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a polypeptide comprising or consisting of a biologically active fragment of the house-dust mite Dermatophagoides pteronyssinus Der p 2.1. Inventors have used a model allergy in a severe asthma allergic (mouse Balbc). They have surprisingly found that when they injected twice the polypeptide derp2.1 in the mouse model after a third asthma attack, the mouse presents a respiratory improvement, reduction of neutrophils and eosinophils in the broncho-alveolar lavage (BAL), an increase of regulators lymphocytes T and reduction of natural killer cells in the BAL. Thus, the polypeptide derp2.1 is a new tool to treat the allergic asthma by a restoration of lung function and reduction of inflammatory environment.

The present invention relates to a composition for prevention or treatment of bronchial asthma comprising a PKR inhibitor as an active ingredient. The PKR inhibitor and derivatives thereof according to the present invention can be used as a pharmaceutical for prevention, amelioration or treatment of bronchial asthma and as a supplementary health food because the PKR inhibitor and derivatives thereof reduce the total counts of inflammatory cells, eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid of neutrophilic severe asthma-induced mice, reduce airway inflammation and airway hyper-responsiveness, and reduce inflammatory mediators.

Provided is a wheeze detection apparatus, a wheeze detection method, and a wheeze detection program which facilitate detection of wheezing during a severe asthma attack or wheezing of a heavy person or a person with a high BMI. The wheeze detection apparatus (1) includes a breathing sound volume deriving unit (43) which derives the breathing sound volume of a subject on the basis of sound measured by a first sound measuring device (M1) for measuring lung sounds from the subject, and a wheezing detection unit (44) which extracts a maximum point from the intensity distribution per frequency of said sound and detects wheezing on the basis of information on the maximum point. The wheezing detection unit (44) sets the detection sensitivity for wheezing to a higher value when the breathing sound volume is outside a specific range than when the breathing sound volume is within the specific range.

The invention discloses application of GAS5 (growth arrest specific 5) in the diagnosis of severe asthma. It is discovered for the first time that GAS5 has a significant upregulation in severe asthma;whether a testee has severe asthma can be judged by detecting the expression level of GAS5. The invention also discloses a significant regulation of the expression level of GAS5 after glucocorticoiddrugs are applied to a severe asthma sample; whether the testee has severe asthma can be judged by detecting the expression level of GAS5 before and after the application of the glucocorticoid drugs;the problem of individual differences can be solved.

Method for the treatment of partly controlled or uncontrolled severe asthma comprising administering either a) a phosphodiesterase 4 (PDE4) inhibitor or b) a phosphodiesterase 4 (PDE4) inhibitor and a leukotriene modifier as add-on to standard of care in severe asthma.

The present invention relates to microfluidic fluidic systems and methods for the in vitro modeling diseases of the lung and small airway. In one embodiment, the invention relates to a system for testing responses of a microfluidic Small Airway-on-Chip infected with one or more infectious agents (e.g. respiratory viruses) as a model of respiratory disease exacerbation (e.g. asthma exacerbation). In one embodiment, this disease model on a microfluidic chip allows for a) the testing of anti-inflammatory and/or anti-viral compounds introduced into the system, as well as b) the monitoring of the participation, recruitment and/or movement of immune cells, including the transmigration of cells. In particular, this system provides, in one embodiment, an in-vitro platform for modeling severe asthma as “Severe Asthma-on-Chip.” In some embodiments, this invention provides a model of viral-induced asthma in humans for use in identifying potentially effective treatments.

The invention discloses an application of 8-isoprostaglandin F2alpha in diagnosis of severe asthma. The invention provides an application of 8-isoprostaglandin F2alpha as a biomarker in preparation of a product for diagnosis or auxiliary diagnosis of severe asthma, which comprises the following steps: detecting the concentration of 8-isoprostaglandin F2alpha in plasma and induced sputum supernatant of an asthma patient; the concentration of 8-isoprostaglandin F2alpha is found to have significant difference in detection samples of severe asthma patients (SA) and non-severe asthma patients (NSA), and meanwhile, by detecting lung function indexes of the asthma patients, the concentration of 8-isoprostaglandin F2alpha in the detection samples is found to have a negative correlation trend with the lung function indexes; the biomarker 8-iso-PGF2 alpha provided by the invention can be conveniently detected through ELISA (Enzyme-Linked Immunosorbent Assay), and the severe asthma can be diagnosed in a simpler and more convenient manner.

The invention discloses application of peripheral blood neutrophil as a severe asthma diagnosis marker. The invention provides application of peripheral blood neutrophil as a marker in preparation of a product for diagnosing severe asthma. According to the present invention, the determination index of severe asthma is obtained by detecting the absolute value and/or the ratio of the peripheral blood neutrophil through the blood routine test of the asthma patient, such that the determination index of severe asthma is determined as follows: the absolute value gt of the peripheral blood neutrophil; 4.55 * 10 < 9 >/L (the sensitivity is 83.3%, and the specificity is 64.0%) or the percentage gt of the neutrophils in the peripheral blood; when the sensitivity is 54.8% and the specificity is 88.0%, the severe asthma is judged, and the AUC of the ROC curve is 0.777 and 0.762 respectively. Results of the invention show that compared with sputum induction, the peripheral blood neutrophil which is more rapid and convenient to detect has a good application prospect in the diagnosis of severe asthma.